PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$2.34B
This Quarter Return
-11.44%
1 Year Return
+13.3%
3 Year Return
+245.82%
5 Year Return
–
10 Year Return
–
AUM
$2.17B
AUM Growth
+$2.17B
(-24%)
Cap. Flow
-$235M
Cap. Flow
% of AUM
-10.8%
Top 10 Holdings %
Top 10 Hldgs %
76.41%
Holding
33
New
5
Increased
11
Reduced
10
Closed
6
Top Buys
| 1 |
Merus
MRUS
|
$70.7M |
| 2 |
Cytokinetics
CYTK
|
$34.5M |
| 3 |
Insmed
INSM
|
$34.4M |
| 4 |
MTSR
Metsera, Inc. Common Stock
MTSR
|
$32.4M |
| 5 |
Cogent Biosciences
COGT
|
$24.2M |
Top Sells
| 1 |
argenx
ARGX
|
$250M |
| 2 |
Vera Therapeutics
VERA
|
$60.8M |
| 3 |
MoonLake Immunotherapeutics
MLTX
|
$44.7M |
| 4 |
Pliant Therapeutics
PLRX
|
$42.1M |
| 5 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$22.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$5.52B
| $374M | 17.12% | 5,269,433 -93,946 | -2% | -$6.66M |
|
2
Arcellx
ACLX
$3.85B
| $295M | 13.5% | 4,492,032 +120,431 | +3% | +$7.9M |
|
3
Revolution Medicines
RVMD
$7.1B
| $218M | 10.01% | 6,178,111 -375,000 | -6% | -$13.3M |
|
|
ONC
4
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $181M | 8.3% | 666,024 +50,000 | +8% | +$13.6M |
|
|
5
Merus
MRUS
$4.98B
| $142M | 6.5% | 3,369,699 +1,679,777 | +99% | +$70.7M |
|
6
Tarsus Pharmaceuticals
TARS
$2.47B
| $134M | 6.14% | 2,610,197 +78,301 | +3% | +$4.02M |
|
7
Edgewise Therapeutics
EWTX
$1.51B
| $96.7M | 4.43% | 4,394,556 -99,373 | -2% | -$2.19M |
|
8
Janux Therapeutics
JANX
$1.37B
| $89.9M | 4.12% | 3,329,909 -186,077 | -5% | -$5.02M |
|
9
Crinetics Pharmaceuticals
CRNX
$2.92B
| $65.3M | 2.99% | 1,946,168 +35,407 | +2% | +$1.19M |
|
10
Vaxcyte
PCVX
$4B
| $64.1M | 2.93% | 1,696,481 +273,694 | +19% | +$10.3M |
|
11
Disc Medicine
IRON
$2.07B
| $60.1M | 2.75% | 1,210,971 -286,749 | -19% | -$14.2M |
|
|
12
Cogent Biosciences
COGT
$1.69B
| $53.7M | 2.46% | 8,963,655 +4,046,243 | +82% | +$24.2M |
|
|
LENZ
13
LENZ Therapeutics
LENZ
$1.1B
| $38.9M | 1.78% | 1,511,932 +741,477 | +96% | +$19.1M |
|
14
Apogee Therapeutics
APGE
$2.17B
| $35.9M | 1.65% | 961,707 -322,059 | -25% | -$12M |
|
|
15
argenx
ARGX
$43.6B
| $35.3M | 1.62% | 59,679 -421,626 | -88% | -$250M |
|
|
16
Cytokinetics
CYTK
$4.23B
| $34.5M | 1.58% | +858,664 | New | +$34.5M |
|
|
17
Insmed
INSM
$28.8B
| $34.4M | 1.58% | +451,359 | New | +$34.4M |
|
18
Spyre Therapeutics
SYRE
$996M
| $34.3M | 1.57% | 2,127,205 +600,000 | +39% | +$9.68M |
|
|
MTSR
19
Metsera, Inc. Common Stock
MTSR
$3.71B
| $32.4M | 1.49% | +1,191,462 | New | +$32.4M |
|
20
Viridian Therapeutics
VRDN
$1.5B
| $28.2M | 1.29% | 2,095,079 +275,000 | +15% | +$3.71M |
|
21
Olema Pharmaceuticals
OLMA
$375M
| $25.3M | 1.16% | 6,741,172 -563,798 | -8% | -$2.12M |
|
|
22
MoonLake Immunotherapeutics
MLTX
$3.54B
| $24.5M | 1.12% | 627,423 -1,144,788 | -65% | -$44.7M |
|
23
Arcutis Biotherapeutics
ARQT
$1.86B
| $22.9M | 1.05% | +1,465,334 | New | +$22.9M |
|
24
Y-mAbs Therapeutics
YMAB
$388M
| $18.8M | 0.86% | 4,236,346 | – | – |
|
25
Erasca
ERAS
$445M
| $14.8M | 0.68% | 10,802,354 +50,000 | +0.5% | +$68.5K |
|